Table 3 ALK inhibitors in clinical use and development

Crizotinib

III

NSCLC

Visual disturbance, nausea, vomiting, constipation, edema

[68-71]

Alectinib

II/III

NSCLC, ALCL, neuroblastoma

Neutropenia, elevated CPK

[79-82]

Ceritinib

II/III

NSCLC

Diarrhea, elevated transaminases

[86-91]

AP-26113

I/II

NSCLC

Nausea, fatigue, diarrhea

[92-94]

ASP-3026

IB

NSCLC

Nausea, vomiting, constipation, abdominal pain

[95,96]

X-376

Preclinical

NSCLC, ALCL, neuroblastoma cell lines

N/A

[98]

X-396

Preclinical

NSCLC, ALCL, neuroblastoma cell lines

N/A

[98]

TSR-011

I/II

NSCLC, pancreatic, ovarian, and salivary gland cancers

Dysaesthesia, QTc prolongation

[99]

CEP-37440

I

NSCLC, SCCHN, colorectal, pancreatic, prostate, and breast cancers

Nausea, vomiting, diarrhea headaches

[100]

NMS-E628

I/II

advanced solid tumors

N/A

[102]

PF-06463922

I/IIA

NSCLC

N/A

[103]